Chinese Journal of Antituberculosis ›› 2022, Vol. 44 ›› Issue (7): 660-668.doi: 10.19982/j.issn.1000-6621.20220012
• Original Articles • Previous Articles Next Articles
YU Chun-hong1, LIU Xing2(), SHEN Ling-jun2(), LI Hai-wen2, LI Xie1, WU Rong-shuang1, LI Xian-rui1, FAN Hao1
Received:
2022-01-23
Online:
2022-07-10
Published:
2022-07-06
Contact:
LIU Xing,SHEN Ling-jun
E-mail:254914514@qq.com;m18608770202@163.com
Supported by:
YU Chun-hong, LIU Xing, SHEN Ling-jun, LI Hai-wen, LI Xie, WU Rong-shuang, LI Xian-rui, FAN Hao. Meta analysis of efficacy and safety of the treatment containing bedaquiline for multidrug-resistant pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2022, 44(7): 660-668. doi: 10.19982/j.issn.1000-6621.20220012
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.19982/j.issn.1000-6621.20220012
文献来源 | 样本量(男/女,例) | 平均年龄(岁) | 平均病程(年) | 干预措施 | 疗程 (周) | 观察指标 | ||||
---|---|---|---|---|---|---|---|---|---|---|
C | T | C | T | C | T | C | T | |||
牟厚玲 2021[ | 31 (24/7) | 32 (21/11) | 34.25± 2.01 | 34.35± 1.95 | 2.59± 0.51 | 2.61± 0.48 | 个体化治疗 方案+Bdq | 个体化治疗 方案 | 24 | ③④⑦ |
常瑞霞 2021[ | 45 (31/14) | 45 (29/16) | 51.6± 4.7 | 52.2± 4.4 | 7.0± 1.4 | 6.8± 1.6 | 个体化治疗 方案+Bdq | 个体化治疗 方案 | 24 | ③⑤⑥⑦ |
任娜 2021[ | 30 (19/11) | 30 (17/13) | 47.12± 12.33 | 46.85± 13.01 | 8.27± 5.57 | 8.08± 5.27 | 个体化治疗 方案+Bdq | 个体化治疗 方案 | 24 | ③④⑤ ⑥⑦ |
凌慧琪 2021[ | 32 (18/14) | 32 (19/13) | 45.35± 4.61 | 45.27± 4.59 | 1.19± 0.13 | 1.20± 0.12 | 个体化治疗 方案+Bdq | 个体化治疗 方案 | 24 | ②③④ ⑤⑥⑦ |
陈艳 2021[ | 69 (44/25) | 60 (45/15) | 34.6± 11.0 | 35.5± 13.82 | - | - | 个体化治疗 方案+Bdq | 个体化治疗 方案 | 24 | ①②③⑧ |
班立芳 2020[ | 53 (31/22) | 52 (32/20) | 42.65± 5.35 | 43.02± 5.40 | 2.96± 0.56 | 2.97± 0.58 | 个体化治疗 方案+Bdq | 个体化治疗 方案 | 24 | ③ |
吴浩宇 2020[ | 34 (19/15) | 34 (20/14) | 41.02± 3.55 | 40.11± 3.82 | 6.03± 2.15 | 5.97± 2.71 | 个体化治疗 方案+Bdq | 个体化治疗 方案 | 24 | ②③④ ⑥⑦ |
Diacon 2009[ | 23 (18/5) | 24 (17/7) | 33 | 33 | - | - | 个体化治疗 方案+Bdq | 个体化治疗 方案 | 24 | ①⑧ |
Diacon 2012[ | 21 (16/5) | 23 (16/7) | 33 | 33 | - | - | 个体化治疗 方案+Bdq | 个体化治疗 方案 | 24 | ①⑧ |
Diacon 2014[ | 66 (45/21) | 66 (40/26) | 32 | 34 | - | - | 个体化治疗 方案+Bdq | 个体化治疗 方案 | 24 | ③⑧ |
纳入研究 | 随机方法 | 分配隐藏 | 盲法 | 结果数据 的完整性 | 选择性报告 研究结果 | 其他偏倚 风险来源 |
---|---|---|---|---|---|---|
牟厚玲2021[ | 门诊单双号 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
常瑞霞2021[ | 患者意愿 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
任娜2021[ | 随机数字表 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
凌慧琪2021[ | 随机 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
陈艳2021[ | 入院时间 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
班立芳2020[ | 随机 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
吴浩宇2020[ | 数字随机表 | 不清楚 | 不清楚 | 是 | 是 | 不清楚 |
Diacon2009[ | 随机 | 恰当 | 双盲 | 是 | 是 | 不清楚 |
Diacon2012[ | 随机 | 恰当 | 双盲 | 是 | 是 | 不清楚 |
Diacon2014[ | 随机 | 恰当 | 双盲 | 是 | 是 | 不清楚 |
[1] |
中国防痨协会. 耐药结核病化学治疗指南(2019年简版). 中国防痨杂志, 2019, 41(10): 1025-1073. doi: 10.3969/j.issn.1000-6621.2019.10.001.
doi: 10.3969/j.issn.1000-6621.2019.10.001 |
[2] |
竺丽梅. 全面完善我国结核病控制策略, 加速遏制结核病进程. 中国热带医学, 2020, 20(10):913-915. doi: 10.13604/j.cnki.46-1064/r.2020.10.01.
doi: 10.13604/j.cnki.46-1064/r.2020.10.01 |
[3] |
中华医学会结核病学分会. 抗结核新药贝达喹啉临床应用专家共识(2020年更新版). 中华结核和呼吸杂志, 2021, 44(2):81-87. doi: 10.3760/cma.j.cn112147-20200714-00805.
doi: 10.3760/cma.j.cn112147-20200714-00805 |
[4] |
Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707):223-227. doi: 10.1126/science.1106753.
doi: 10.1126/science.1106753 pmid: 15591164 |
[5] | World Health Organization. WHO Consolidated guidelines on tuberculosis. Module 4: treatment-drug-resistant tuberculosis treatment. Geneva: World Health Organization, 2020. |
[6] |
牟厚玲. 贝达喹啉治疗耐多药肺结核的疗效及安全性观察. 河北医药, 2021, 43(19):2955-2957,2961. doi: 10.3969/j.issn.1002-7386.2021.19.018.
doi: 10.3969/j.issn.1002-7386.2021.19.018 |
[7] |
常瑞霞, 可春梅. 贝达喹啉治疗耐多药结核病的疗效和安全性. 临床药物治疗杂志, 2021, 19(3):57-60. doi: 10.3969/j.issn.1672-3384.2021.03.011.
doi: 10.3969/j.issn.1672-3384.2021.03.011 |
[8] |
任娜, 胡善雷, 刘金瑾, 等. 富马酸贝达喹啉片治疗耐多药肺结核的疗效观察. 临床肺科杂志, 2021, 26(7):1047-1051. doi: 10.3969/j.issn.1009-6663.2021.07.018.
doi: 10.3969/j.issn.1009-6663.2021.07.018 |
[9] |
凌慧琪, 陈伟杰, 何显科. 富马酸贝达喹啉片治疗耐多药肺结核的临床疗效分析. 广西医科大学学报, 2021, 38(7):1442-1447. doi: 10.16190/j.cnki.45-1211/r.2021.07.032.
doi: 10.16190/j.cnki.45-1211/r.2021.07.032 |
[10] |
陈艳, 陈竹, 黄涛, 等. 含贝达喹啉的联合方案治疗耐多药结核病的疗效及安全性研究. 华西医学, 2021, 36(10):1392-1398. doi: 10.7507/1002-0179.202006302.
doi: 10.7507/1002-0179.202006302 |
[11] |
班立芳, 马峥, 孔庆飞, 等. 贝达喹啉对耐多药肺结核患者免疫功能及细胞因子的影响. 检验医学与临床, 2020, 17(16):2292-2294. doi: 10.3969/j.issn.1672-9455.2020.16.006.
doi: 10.3969/j.issn.1672-9455.2020.16.006 |
[12] |
吴浩宇. 贝达喹啉联合常规抗结核药物治疗耐多药肺结核的效果观察. 中国医药指南, 2020, 18(29):48-49. doi: 10.15912/j.cnki.gocm.2020.29.022.
doi: 10.15912/j.cnki.gocm.2020.29.022 |
[13] |
Diacon AH, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med, 2009, 360(23): 2397-2405. doi: 10.1056/NEJMoa0808427.
doi: 10.1056/NEJMoa0808427 URL |
[14] |
Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother, 2012, 56(6): 3271-3276. doi: 10.1128/AAC.06126-11.
doi: 10.1128/AAC.06126-11 pmid: 22391540 |
[15] |
Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014, 371(8):723-732. doi: 10.1056/NEJMoa1313865.
doi: 10.1056/NEJMoa1313865 URL |
[16] |
卢春容, 房宏霞, 陆普选, 等. WHO 2021年全球结核病报告: 全球与中国关键数据分析. 新发传染病电子杂志, 2021, 6(4): 368-372. doi: 10.19871/j.cnki.xfcrbzz.2021.04.023.
doi: 10.19871/j.cnki.xfcrbzz.2021.04.023 |
[17] |
Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment-2017, Ahmad N, Ahuja SD, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018, 392(10150):821-834. doi: 10.1016/S0140-6736(18)31644-1.
doi: 10.1016/S0140-6736(18)31644-1 URL |
[18] |
Gao M, Gao J, Xie L, et al. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: a multicentre study. Clin Microbiol Infect, 2020, 27(4):597-602. doi: 10.1016/j.cmi.2020.06.004.
doi: 10.1016/j.cmi.2020.06.004 URL |
[19] | World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: Interim policy guidance[M/OL]. [2021-12-06]. |
[20] |
杨松, 严晓峰. 贝达喹啉治疗耐多药与广泛耐药结核病的现状和展望. 结核病与肺部健康杂志, 2019, 8(4):249-252. doi: 10.3969/j.issn.2095-3755.2019.04.004.
doi: 10.3969/j.issn.2095-3755.2019.04.004 |
[21] |
谢莉, 高静韬, 马丽萍, 等. 含贝达喹啉方案治疗耐多药肺结核对患者心电图QT间期的影响. 中国防痨杂志, 2020, 42(7):687-694. doi: 10.3969/j.issn.1000-6621.2020.07.009.
doi: 10.3969/j.issn.1000-6621.2020.07.009 |
[22] |
Pontali E, Sotgiu G, Tiberi S, et al. Cardiac safety of bedaquiline: a systematic and critical analysis of the evidence. Eur Respir J, 2017, 50(5):1701462. doi: 10.1183/13993003.01462-2017.
doi: 10.1183/13993003.01462-2017 URL |
[23] |
Meyvisch P, Kambili C, Andries K, et al. Evaluation of six months sputum culture conversion as a surrogate endpoint in a multidrug resistant-tuberculosis trial. PLoS One, 2018, 13(7): e200539. doi: 10.1371/journal.pone.0200539.
doi: 10.1371/journal.pone.0200539 |
[24] |
胡春梅, 方刚, 张向荣, 等. 贝达喹啉联合常规抗结核药物治疗耐多药肺结核患者的长期疗效及安全性观察. 国际医药卫生导报, 2018, 24(5):711-715. doi: 10.3760/cma.j.issn.1007-1245.2018.05.028.
doi: 10.3760/cma.j.issn.1007-1245.2018.05.028 |
[1] | LIU Hai-ting, LI Dong-shuo, ZHANG Lei, WANG Ning, WANG Bin, DING Yang-ming, YAO Rong, LU Yu. A preliminary study on the synergy and mechanism of pyrifazimine and bedaquiline [J]. Chinese Journal of Antituberculosis, 2022, 44(7): 646-653. |
[2] | DONG Zhao-liang, YAO Li-ming, WANG Lian-bo, JIA Chen-guang, YAO Xiao-wei, LIU Shu-ren, LIU Feng-sheng, WANG Shuai. Analysis of effectiveness of short-course preoperative chemotherapy in rapid recovery of patients with single-segment spinal tuberculosis anterior surgery [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 559-564. |
[3] | LI Zhi-wei, LAI Keng, LI Tie-gang, LIANG Zi-chao, DU Yu-hua, ZHANG Jin-xin. Analysis of adverse treatment outcomes and influencing factors of drug-resistant tuberculosis patients in Guangzhou from 2016 to 2020 [J]. Chinese Journal of Antituberculosis, 2022, 44(6): 600-607. |
[4] | XIE Li, ZHU Hui, GAO Jing-tao, LIU Zhong-quan, MA Li-ping, ZHANG Li-qun, GE Qi-ping, NIE Li-hui, KONG Zhong-shun, WU Xiao-guang, LIU Rong-mei, CHEN Hong-mei, SONG Yan-hua, LI Qiang, LYU Zi-zheng, LIU Yu-hong, LU Yu, PANG Yu, GAO Meng-qiu. Changes of plasma concentration of bedaquiline during the treatment of drug-resistant pulmonary tuberculosis and its assocation with QTc interval prolongation [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 219-226. |
[5] | LI Dong-shuo, WANG Bin, LU Yu, XU Jian. Study of expression and function of Mycobacterium tuberculosis membrane protein MmpL5-MmpS5 [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 227-233. |
[6] | ZHANG Yu-xia, XIONG Yu, CHANG Ting-ting, LIU Feng-xia. Analysis of adverse reactions of bedaquiline containing regimen in the treatment of drug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 239-245. |
[7] | QI Qi, CAI Qing-shan, CUI Yan-fei, CHEN Yuan-yuan, BAO Zhi-jian, QIU Mei-hua, GUO Yi-nan, MA Xiao-qing. Effect of Roast Radix Glycyrrhizae Decoction Granules on the prolongation of QT interval caused by bedaquiline in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2022, 44(3): 246-251. |
[8] | DING Cai-hong, XIONG Yu, WANG Qing, GAO Xu-sheng, HAO Yan. Study on the early efficacy and safety of the regimen containing bedaquiline in the treatment of multidrug-resistant pulmonary tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 893-898. |
[9] | WU Guo-lan, GAO Jing-tao, CHEN Xiao-hong, CHEN Li-zhou, WENG Li-zhen, GUO Zhi-ping, CHEN Xiu-ping, LIN Jian-dong, CHEN Su-xia, GAO Meng-qiu, LIU Yu-hong. Short-term effectiveness and safety of a regimen containing bedaquiline in the treatment of multidrug-resistant/extensively drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(9): 899-904. |
[10] | QIN Yao, CAI Qing-shan, BAO Zhi-jian. Analysis of clinical characteristics and prognosis of 21 pregnant women complicated with tuberculosis after in vitro fertilization-embryo transfer [J]. Chinese Journal of Antituberculosis, 2021, 43(7): 682-688. |
[11] | XUE Hai-bin, LUO Xiao-bo, SUN Fei, JIAN Wei, LI Jin-long. Analysis of clinical efficacy of posterior transforaminal debridement and interbody fusion with instrumentation via tubular retractor system for lumbar tuberculosis [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 457-462. |
[12] | WANG Lu, XUE Zhong-tan, WANG Yu-feng, SHANG Yuan-yuan, REN Wei-cong, YAO Cong, GAO Fei, PANG Yu. A study of dynamic monitoring of drug sensitivity of Mycobacterium tuberculosis to bedaquiline and the mechanism of drug resistance [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 482-486. |
[13] | SHI Zheng-yu, WU Gui-hui, HUANG Tao, LIU Yu-hong, GAO Meng-qiu, CHEN Lei, LI Xi, YANG Ming, HE Wei, CHEN Yan, LU Xiao-li, GAO Jing-tao, LI Liang. Early effectiveness and safety of bedaquiline containing regimen in treatment of multidrug-resistant and extensively drug-resistant tuberculosis: An one arm observational study of 24 weeks [J]. Chinese Journal of Antituberculosis, 2021, 43(5): 487-494. |
[14] | Maiweilanjiang· Abulimiti, Diermulati· Tusun, LIU Zhen-jiang, Xirizhati· Mamuti, LI Guan-zhen, OU Xi-chao. Analysis on the therapeutic effect and influencing factors of initial treated smear-positive pulmonary tuberculosis patients in Kashgar Prefecture from 2016 to 2018 [J]. Chinese Journal of Antituberculosis, 2021, 43(4): 391-397. |
[15] | YANG Ni, SU Qian, XIAO Yue, LU Jia, SONG Yang, RAO Zheng-yuan, XIA Lan, HE Jin-ge, CHEN Chuang, ZHANG Ling-lin. Analysis on treatment outcomes and influencing factors of 2158 patients with MTB/HIV co-infection [J]. Chinese Journal of Antituberculosis, 2021, 43(3): 274-279. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||